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Summary
Objective: To verify the involvement of proinﬂammatory cytokines IL-17, IL-1b and tumor necrosis factor a (TNF-a) in cartilage vascularization
by stimulating the production of vascular endothelial growth factor (VEGF) by chondrocytes isolated from patients with osteoarthritis (OA), in
comparison with patients with rheumatoid arthritis (RA) and patients with femoral or humeral neck fracture (FP).
Design: Chondrocytes isolated from patients with OA were maintained in monolayer culture for several passages. Chondrocyte
dedifferentiation was monitored by the synthesis of cathepsin B by these cells. Chondrocytes freshly isolated at each subculture (subcultures
1e3) were stimulated with IL-17, IL-1b or TNF-a. Supernatants were collected, immunoassayed for the production of VEGF and cathepsin B
and assayed as the source of VEGF on the VEGF sensible ECV304 cell line. The cells were used to quantify intracellular cathepsin B
enzymatic activity.
Results: In differentiated conditions IL-1b and TNF-a, but not IL-17, can inhibit the spontaneous secretion of VEGF by human OA, RA and FP
chondrocytes, and IL-17 can restore the decrease in VEGF secretion caused by TNF-a. IL-17, together with IL-1b and TNF-a, can enhance
VEGF secretion to various extents by dedifferentiated OA chondrocytes. This change in effect with respect to primary culture was observable
for all cytokines at the beginning of dedifferentiation, when the production of VEGF by chondrocytes had dramatically fallen and the cathepsin
B synthesis had increased. The amount of VEGF induced by cytokines on dedifferentiated chondrocytes never reached the amount of VEGF
produced by differentiated chondrocytes. VEGF produced by chondrocytes stimulated the ECV304 cell line proliferation.
Conclusions: These results indicate that dedifferentiated OA chondrocytes secrete VEGF after stimulation with proinﬂammatory cytokines.
This event may be responsible for neovascularization found in OA cartilage.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a multifactorial disease of unknown
origin, associated with structural changes in all articular
tissues. It is characterized by synovial ﬁbrosis and cartilage
erosion that induce subchondral bone damages1. OA is
also characterized by an evident inﬂammation: synovial
hypertrophy, proliferation of synovial lining cells, presence
of inﬁltrate in sublining tissue2. The presence of inﬂamma-
tion in OA, that in some cases resembles that found in
rheumatoid arthritis (RA)3,4, has been associated with the
progression of OA5. Cartilage is normally an avascular
tissue, but OA damaged cartilage presents vascularized
zones. Angiogenesis is a process stimulated in chronic joint
inﬂammation6, and among factors able to promote endo-
thelial cell proliferation and migration, vascular endothelial
growth factor (VEGF) is one of the most important up-
regulators of vasculogenesis7. VEGF is a 46e48 kDa
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Received 4 August 2003; revision accepted 17 May 2004.683glycosylated homodimeric polypeptide, which shows sev-
eral variants. The main ones include 121, 145, 165, 189 and
206 amino acids. These isoforms present different abilities
to bind to extracellular matrix proteoglycans and to VEGF
receptors8. The expression of VEGF has been demon-
strated in synovial membrane of OA patients9,10, although
the serum VEGF concentration was normal11. It is debated
whether VEGF is expressed by normal adult cartilage, but
chondrocytes are a source of VEGF in OA cartilage12e14.
Some physical and chemical factors that can stimulate the
secretion of VEGF in inﬂamed tissues are hypoxia6,
prostaglandin E (PGE) 1 and 215, proinﬂammatory cyto-
kines such as IL-1b and IL-616,17.
IL-17, IL-1b and tumor necrosis factor a (TNF-a) are
proinﬂammatory cytokines over-expressed in articular OA
tissues that contribute to the pathogenesis of OA2,5,18,19. It
is known that IL-1b and TNF-a can induce chondrocyte
dedifferentiation20,21 and OA chondrocytes express some
dedifferentiation markers, such as types I and III collagen
and cathepsin B21e23. So, the model of ‘‘in vitro’’
dedifferentiating chondrocytes can be important to study
the release of growth factors inﬂuencing cartilage neo-
vascularization.
The aim of our study was to verify whether the
proinﬂammatory cytokines IL-17, IL-1b and TNF-a were
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at different differentiation stages.
Our results indicated that IL-17, together with IL-1b and
TNF-a, can enhance VEGF secretion to various degrees by
dedifferentiated chondrocytes. In differentiated conditions
IL-1b and TNF-a, but not IL-17, can inhibit the spontaneous
secretion of VEGF by human chondrocytes and IL-17 can
restore the decrease in VEGF secretion caused by TNF-a.
Materials and methods
TISSUE SAMPLES AND PATIENTS
The study was performed on 17 patients with OA (mean
age 64 years, range 44e75) undergoing knee (14 cases) or
hip (three cases) replacement surgery. Diagnosis of OA
was based on clinical, radiological and laboratory param-
eters24. All patients involved in the study showed grade
IIIeIV radiological features according to the Kellgren and
Lawrence grading system25. Five patients with RA (mean
age 57 years, range 24e74) undergoing knee (three cases)
or hip (two cases) replacement surgery were used for
comparison. Diagnosis of RA was made according to
American College of Rheumatology criteria26. Besides,
human cartilage was obtained from femoral ( four cases)
or humeral (one case) heads removed after fracture in ﬁve
patients with no history or articular morphological alterations
of OA (FP) (mean age 70 years, range 43e87). The study
was approved by the ethical committee of Istituti ortopedici
Rizzoli and informed consent was obtained from the
patients.
CHONDROCYTE ISOLATION AND CULTURE CONDITIONS
Articular cartilage tissue was removed from the medial
condyles or tibial plateau. As expected, the cartilage
samples were macroscopically different and erosion areas
were present. During tissue sampling, regions with evident
signs of erosion were avoided. The remaining fragments of
cartilage tissue from each patient were pooled together
before digestion. Chondrocytes were isolated by sequential
enzymatic digestion of cartilage as previously described19.
Chondrocytes obtained were resuspended in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Gibco BRL, Grand
Island, NY, USA) supplemented with 4 mM glutamine
(Sigma, St. Louis, MO, USA), 200 mg/ml gentamycin (Flow
Laboratories, Biaggio, Switzerland) and 10% heat inacti-
vated fetal calf serum (FCS) (Gibco BRL) (complete
medium), seeded in 96-well ﬂat-bottom microplates at
a density of 1!105 and 27!105 cells/cm2 in 0.2 ml of
complete DMEM and in T 75 culture ﬂask (1!105 cells/
cm2) and maintained at 37(C in 5% CO2 humidiﬁed
atmosphere. When chondrocytes seeded in T 75 culture
ﬂask were conﬂuent (after 10e15 days of culture), they
were trypsinized (0.05% trypsin/0.5 mM EDTA, Sigma),
washed and split 1:3 to obtain subsequent passages. Under
these conditions of culture each subculture represents a 1.5
cell doubling27e29. Chondrocytes freshly isolated and at the
different passages were used for experiments. Cell viability,
determined by the eosin dye exclusion test, was always
higher than 95%.
CHONDROCYTE STIMULATION
All experiments were performed in a 96-well ﬂat-bottom
microplate in 0.2 ml of complete culture medium using
chondrocytes, either freshly isolated, between the ﬁrst andthird subcultures ( primary culture and subcultures 1e3,
seeded at 2!105 cells/cm2), or as primary culture which
had begun to actively proliferate ( proliferating primary
culture, seeded at 1!105 cells/cm2). After overnight, or in
proliferating primary culture, 0.1 ml was substituted with
0.1 ml of complete medium with or without stimuli: 50 ng/ml
recombinant human (rh) IL-17 (IL-17) (R&D Systems,
Minneapolis, MN, USA), 100 U/ml rhIL-1b (IL-1b; speciﬁc
activity 5!107 U/mg) (Boehringer, Mannheim, Germany),
100 U/ml rhTNF-a (TNF-a; speciﬁc activity 1!108 U/mg)
(Boehringer) ( ﬁnal concentration). Chondrocytes were also
stimulated with IL-17/IL-1b or IL-17/TNF-a, as described for
each experiment. After an incubation of 72 h, supernatants
were collected and maintained at 80(C until their use.
Previous experiments had shown that these stimulation
conditions were adequate to detect soluble VEGF produced
by chondrocytes at all used subcultures; chondrocytes at
subculture 3, maintained without stimuli, needed at least
48 h to secrete detectable amounts of VEGF by an enzyme-
linked immunosorbent assay (ELISA). Bovine serum albu-
min in PBS added to the complete medium at the same
concentration of the cytokine preparation used to stimulate
the chondrocyte cultures did not affect the secretion of
VEGF by chondrocytes in non-stimulated conditions.
CELL LINE CULTURE AND PROLIFERATION ASSAY
A human umbilical cord transformed endothelial cell line,
ECV304 (American Type Culture Collection, Rockville, MD,
USA), which is known to be stimulated to proliferate in the
presence of VEGF30, was maintained in culture in medium
199 supplemented with 4 mM glutamine (Sigma), 200 mg/ml
gentamycin (Flow Laboratories) and 10% heat inactivated
FCS (Gibco BRL) ( growth medium). For proliferation assay,
ECV304 was seeded in 96-well ﬂat-bottom microplates in
0.2 ml of growth medium at 1.25!103 cells/well. After 8 h of
incubation, the growthmediumwas substituted with 0.2 ml of
medium 199 supplemented with 2% FCS to reduce the
normal high proliferation speed and to highlight the stimulat-
ing effect of VEGF better. After further 14 h, 5 ng/ml
recombinant VEGF165 (rVEGF) (R&D Systems) in complete
DMEM or supernatants from 72 h stimulated OA chondro-
cytes as conditioned medium (CCM), both 1:2 diluted with
serum-free medium 199, were used to substitute the culture
medium. At the end of 10 h incubation, the cells, pulsed with
0.5 mCi per well of [methyl-3H]-thymidine (ICN Biomedicals,
Irvine, CA, USA) in the last 4 h, were collected onto glass-
ﬁber ﬁlters, using an automatic cell collector (Filtermate 196,
Packard Instrument Company, Meriden, CT, USA) and cpm
values from cultures were counted with a liquid scintillation
counter (Topcount B99020, Packard Instrument Company).
The cell number per well, rVEGF concentration, culture
mediums and incubation times were based on results
obtained in previous experiments performed to assess the
optimal conditions to detect the CCM effect on ECV304 cell
line proliferation. The speciﬁcity of the VEGF proliferative
response was evaluated by incubating the ECV304 cell line
for 1 h at 37(C with the indicated concentrations of anti-
VEGF receptor 2 antibody (anti-VEGFR-2) (R&D Systems)
before the addition of rVEGF or culture supernatants (CCM).
Each assay was conducted in triplicate.
ELISA ASSAY FOR VEGF
VEGF secreted by non-stimulated and stimulated chon-
drocytes was determined in the supernatant of 72 h culture
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following the manufacturer’s recommended protocol. Quan-
tikine recognizes VEGF121, VEGF165 and naturally occur-
ring human VEGF; so, most of the VEGF detected in our
samples was VEGF121, the secreted isoform, soluble and
not binding heparan sulfate or extracellular matrix8. To
better compare the VEGF secretion by chondrocytes at
different culture passages, for each sample we normalized
the amount of VEGF to 105 cells in view of the fact that
chondrocytes in primary culture did not show evident
proliferating activity during 72 h of culture; on the contrary,
chondrocytes in proliferating primary culture were seeded at
lower density, but received the stimuli after various pro-
liferation cycles and subcultures 1e3 were stimulated being
in the logarithmic growth phase, until reaching conﬂuence
within the 72 h of stimulation.
To determine the number of cells present in each well
evaluated for VEGF release, a PicoGreen dsDNA
Quantitation kit (Molecular Probes, Eugene, OR, USA) for
double strand DNA assay was used. After collecting
supernatants, adherent cells were lysed by adding 100 ml
lysant buffer (cell-lysis buffer of CyQUANT Cell Pro-
liferation Assay Kit, Molecular Probes) to each well and
then 100 ml of working solution of the PicoGreen reagent
was added. After 5 min incubation at room temperature in
the dark, the ﬂuorescence of the samples was determined
using a Spectramax Gemini dual-scanning microplate
spectroﬂuorimeter (Molecular Device, Sunnyvale, CA,
USA) (480 nm excitation, 540 nm emission and 515 nm
cut-off), in the well-scan mode. The ﬂuorescence of each
sample was compared with the ﬂuorescence of a curve
obtained with 1:2 (scalar) dilutions of chondrocytes from
0.5!106 to 0.016!106 or with a curve of standard DNA.
CATHEPSIN B ASSAY
Cathepsin B secreted by chondrocytes was evaluated in
the supernatant of primary and proliferating primary cultures
by a speciﬁc ELISA test, following the manufacturer’s
recommended protocol (Human Cathepsin B ELISA test,
KRKA, Novo Mesto, Slovenia). The detection limit was
0.03 nmol/l. The amount of intracellular cathepsin B present
in chondrocytes at the end of 72 h of culture was
determined on primary and proliferating primary cultures
for each patient, at basal condition. Cathepsin B assay was
performed following the method described by Zwicky and
Baici31, with minor modiﬁcations. Brieﬂy, at the end of the
culture, after collecting supernatant, the cell layer was
washed twice with physiological solution and then the plate
was frozen at 80(C until the cathepsin B assay. Then,
0.2 ml of DMEM without phenol red was added to each well
and the plates were sonicated in a cool water bath ( ﬁve
cycles of 2 s, 5 s intervals). The suspension was centri-
fuged at 2000g for 15 min at 4(C and 10 ml of supernatant
was incubated with 200 ml of 0.5 mM N-carbobenzoxy-
L-arginyl-L-arginyl-7-(4-methyl)-coumarylamide (Z-arg-arg-
Nmec; Bachem, Budendorf, Switzerland) in 100 mM
sodium phosphate buffer pH 6 containing 2 mM EDTA and
2 mM dithiothreitol for 6 h at 25(C in the dark under gentle
shaking. The reaction was stopped by adding 5 ml of 68 mM
iodoacetic acid. The ﬂuorescence of each sample evaluated
in triplicate was determined using a Spectramax Gemini
dual-scanning microplate spectroﬂuorimeter (Molecular
Device, Sunnyvale, CA, USA) (383 nm excitation, 455 nm
emission and 435 nm cut-off), in the end point mode, and
compared with 5 mM 7-amino-4-methyl-coumarin (Bachem)used as ﬂuorimetric standard. Cathepsin B activity was
expressed as biological units (U) for 105 cells. One biological
unit corresponded to the amount of enzyme necessary to
hydrolyze 1 nmol of substrate.
STATISTICAL ANALYSIS
Parametric and nonparametric tests were used for
statistical analysis of the results; differences between
groups were compared by the Student’s t-test or by the
ManneWhitney U test and when the Friedman ANOVA test
for multiple comparison was signiﬁcant, paired data were
analyzed by the Wilcoxon matched pairs test; correlations
were analyzed by the Spearman test.
Results
VEGF SECRETION BY CHONDROCYTES
Chondrocytes from all subjects constitutively released
VEGF immediately after isolation ( primary culture), but the
level of VEGF released by OA or RA chondrocytes was
higher than that released by FP chondrocytes (Fig. 1).
VEGF secretion by OA and RA samples was not statistically
different. Chondrocytes from OA patients were also
evaluated for VEGF secretion at different subcultures. Eight
to 25 days (mean timeGSD, 12.0G4.9 days) were
necessary to observe an active proliferation of chondro-
cytes seeded at 1!105 cells/cm2 after isolation, depending
on individual variability. At this time ( proliferating primary
culture), cultures were stimulated for 72 h. Interestingly, we
veriﬁed that a strong decrease of VEGF secretion was
obtained by proliferating primary culture from all subjects
evaluated, compared to cells in primary culture, also when
the beginning of proliferation by primary culture was
reached after only 8 days of culture. The effect of the sub-
culturing was a progressive decrease of VEGF secretion
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Fig. 1. Production of VEGF by freshly isolated chondrocytes. Data
are represented from chondrocytes of 15 OA subjects, ﬁve RA
subjects and ﬁve subjects with femoral or humeral neck fracture
(FP). Results are expressed as pg/ml of VEGF secreted by
chondrocytes seeded at 2!105 cells/cm2 and not showing any
proliferation at the end of 72 h culture. The boxes show 25th and
75th percentiles, the symbols the medians, and the vertical lines
below and above the boxes 10th and 90th percentiles. Statistical
comparison was carried out using the ManneWhitney U test.
*P!0:05 and **P!0:01 vs FP subjects.
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correlation r ¼ 0:831; P!0:01) (Fig. 2).
DIFFERENTIATION DEGREE OF CULTURED OA CHONDROCYTES
The differentiated morphology shown by primary culture
of OA chondrocytes (rounded cells, presence of cell
clusters, typical for freshly isolated chondrocytes and
cultured for 4 days) was lost when cells began to proliferate
to reach conﬂuence and assumed the appearance of
polygonal cells, uniformly distributed into the culture plate
( proliferating primary culture). In subcultures 1e3 chondro-
cytes had become ﬁbroblast-like cells. To establish whether
the different VEGF production by chondrocytes in primary
and proliferating primary cultures was due to the degree of
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Fig. 2. Effect of subculture on VEGF production by OA chondro-
cytes. Data are represented from chondrocytes of 15 subjects in
primary culture ( p) and in proliferating primary culture ( pp), 13
subjects in subcultures 1 and 2 (sub 1 and sub 2). Results are
expressed as pg of VEGF secreted by 105 cells, on the basis of the
number of cells present in each well at the end of 72 h of culture in
non-stimulated conditions. The boxes show 25th and 75th
percentiles, the symbols the medians, and the vertical lines below
and above the boxes 10th and 90th percentiles. Statistical
comparison was carried out using the Wilcoxon matched pairs
test. **P!0:01 vs p.chondrocyte differentiation, we compared the cathepsin B
synthesis with VEGF production by chondrocytes in these
two culture conditions, cathepsin B being a marker of
chondrocyte dedifferentiation23. We veriﬁed that the effect
of few culture days was evident also in cathepsin B
synthesis by chondrocytes, because the activity present in
the intracellular pool of and the protein released into the
supernatant by chondrocytes in primary culture consider-
ably increased when cells were in proliferating primary
culture (Fig. 3), while VEGF production decreased from
primary to proliferating primary culture.
DIFFERENT EFFECT OF CYTOKINES ON VEGF SECRETION BY
CULTURED OA CHONDROCYTES
The ability of primary culture of OA chondrocytes to
release VEGF was not affected by IL-17, but when
chondrocytes were stimulated by IL-1b or TNF-a the
release of VEGF decreased compared to non-stimulated
controls or IL-17-stimulated cells. IL-1b and TNF-a had
a similar effect [Fig. 4(a)]. On the contrary, IL-17, IL-1b and
TNF-a stimulated VEGF secretion in proliferating primary
culture and subcultures 1 and 2, when chondrocytes were
tending to lose their ability to secrete VEGF [Fig. 4(bed)].
Most of the cartilage tissue (14/17) was obtained during
knee surgery. We did not detect any difference in VEGF
production or cytokine effect between hip (three cases) and
knee (14 cases) cartilage samples. IL-1b stimulated the
secretion of higher amounts of VEGF compared to IL-17 in
subcultures 1 and 2, and compared to TNF-a in proliferating
primary culture, subcultures 1 and 2 [Fig. 4(bed)]. Only
three subjects were evaluated through to subculture 3 and
at this passage their chondrocytes showed the same trend:
the basal secretion of VEGF was lower than that at
subculture 2 and was increased by IL-17, IL-1b and TNF-
a (data not shown). The effect of the proliferation in
monolayers was also a progressive decrease of VEGF
secretion by stimulated chondrocytes from primary culture
to subculture 3 (Spearman correlation: r ¼ 0:783 and
P!0:01, r ¼ 0:478 and P!0:01, r ¼ 0:579 and
P!0:01, for IL-17, IL-1b and TNF-a stimulation, respec-
tively). These cytokines, although increased the VEGF
secretion by cultured chondrocytes, did not restore the high
VEGF secretion shown by non-stimulated chondrocytes in
primary culture [Fig 4(aed)].a
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Fig. 3. Metabolic differences between primary culture ( p) and proliferating primary culture ( pp) of chondrocytes. Chondrocytes from seven OA
subjects had been evaluated for their cathepsin B synthesis and VEGF production. To compare the activity of chondrocytes at p and pp, which
presented samples with evident differences in cell numbers, we normalized each result to 105 cells. (a) Cathepsin B as intracellular enzymatic
activity at the end of 72 h culture is shown and expressed as biological units (U, amount of enzyme necessary to hydrolyze 1 nmol of
substrate); (b) cathepsin B released in the supernatant of 72 h culture; (c) VEGF released in the supernatant of 72 h culture. Statistical
comparison was made using the Wilcoxon matched pairs test. *P!0:05 and **P!0:01 vs p.
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Fig. 4. Effect of cytokines and passages in culture on VEGF production by OA chondrocytes. Data are represented from 15 subjects in primary
culture and in proliferating primary culture and 13 subjects in subcultures 1 and 2. Results are expressed as pg of VEGF secreted by 105 cells
incubated for 72 h in non-stimulated conditions (NS) or with IL-17 (50 ng/ml), IL-1b (100 U/ml) or TNF-a (100 U/ml). The boxes show 25th and
75th percentiles, the symbols the medians, and the vertical lines below and above the boxes 10th and 90th percentiles. Statistical comparison
was made using the Wilcoxon matched pairs test. (a) **P!0:01 vs NS and IL-17-stimulated chondrocytes; (b) **P!0:01 vs NS; #P!0:05 vs
TNF-a-stimulated chondrocytes; (c) **P!0:01 vs NS; xxP!0:01 vs IL-17- and TNF-a-stimulated chondrocytes; (d) *P!0:05 vs NS; xP!0:05
vs IL-17- and TNF-a-stimulated chondrocytes.EFFECT OF IL-17 ON VEGF SECRETION STIMULATED BY IL-1b OR
TNF-a ON OA CHONDROCYTES
We also investigated the combined effect of IL-17 with IL-
1b or TNF-a on VEGF secretion. Chondrocytes from ﬁve
OA patients were utilized to control the additional effect of
IL-17 on primary and proliferating primary cultures and
subculture 1 stimulated with IL-1b or TNF-a. Three of the
ﬁve OA patients were also utilized in subculture 2. Although
IL-17 did not affect the release of VEGF by primary cultures
of chondrocytes, when freshly isolated OA chondrocytes
were stimulated by TNF-a, the additional presence of IL-17
was able to induce a secretion of VEGF as high as that
constitutively released by chondrocytes and the inhibiting
effect of TNF-a was eluded. On the contrary, IL-17 did not
restore the release of VEGF decreased by IL-1b compared
with non-stimulated or IL-17-stimulated chondrocytes [Fig.
5(a)]. When we used OA chondrocytes in proliferating
primary culture and subcultures 1 and 2, we did not obtain
any additional effect of IL-17 on cultures stimulated by IL-1b
or TNF-a [Fig. 5(bed)].
BIOLOGICAL EFFECT OF VEGF RELEASED BY CHONDROCYTES
To verify if IL-17, IL-1b and TNF-a could cause neo-
vascularization by increasing VEGF released by OA
chondrocytes, the biological effect of the CCM, containing
VEGF, on the proliferation of the EVC304 cell line was
evaluated by [methyl-3H]-thymidine incorporation and com-
pared with the effect of rVEGF.
The effect of rVEGF was dose-dependent on 1e25 ng/ml
in all evaluated cell numbers per well (ranging0.312e2.5!103 cell/well) (data not shown). At a density
of 1.25!103 cells/well the pre-incubation with anti-VEGFR-
2 antibody (100e1000 ng/ml) completely blocked the 42%
increase of [methyl-3H]-thymidine incorporation by ECV304
cell line stimulated by 5 ng/ml rVEGF. On the contrary,
50 ng/ml anti-VEGFR-2 antibody was not able to completely
block the effect of rVEGF (P!0:05 vs non-stimulated
control) [Fig. 6(a)]. CCM obtained by 72 h incubated
chondrocytes in the absence of stimuli or presence of IL-
17, IL-1b or TNF-a were chosen among chondrocyte
supernatants containing different VEGF amounts ranging
from 0.54 to 12.8 ng/ml, that corresponded to 0.27e6.4 ng/
ml when diluted in proliferation tests. The ECV304 cell line
incubated with CCM showed a higher increase in pro-
liferation than that induced by 5 ng/ml rVEGF (44%),
compared with the proliferation in the presence of medium
alone [Fig. 6(b)]. Neutralization of VEGFR-2 with speciﬁc
antibodies decreased but did not completely inhibit the
proliferation induced by CCM, that remained higher than the
one obtained by spontaneously proliferating ECV304 cell
line (P!0:05 at least). Thus, the CCM effect seems to be
not only dependent on VEGF, but also on other growth
factors which could interfere with VEGF-induced chondro-
cyte proliferation. As a control, the EVC304 cell line was
also incubated in the presence of IL-17, IL-1b or TNF-a at
the concentrations same as those used to obtain CCM, and
the incorporation of [methyl-3H]-thymidine was comparable
to that obtained at basal conditions. This ﬁnding allowed us
to exclude the hypothesis that the higher ECV304 cell line
proliferation obtained by CCM, compared with the culture
stimulated by rVEGF or maintained without stimuli, was due
to IL-17, IL-1b or TNF-a present in CCM.
688 M. C. Honorati et al.: Cytokines and chondrocyte VEGF productionNS
IL-17
IL-1β
TNF-α
IL-17 + IL-1β
IL-17 + TNF-α
0
4000
8000
12000
16000
proliferating primary culture
b
*
*
*
*
*
01/gp
5
sll
ec
4000
8000
12000
16000
20000
0
primary culture
a
§
*
§ §
*
*
c
0
2000
4000
6000
8000
10000
01/gp
5
sll
ec
subculture 1
*
*
*
*
*
subculture 2
d
0
1000
2000
3000
4000
5000
6000
*
*
*
*
*
Fig. 5. Effect of IL-17 on IL-1b- or TNF-a-stimulated VEGF secretion by OA chondrocytes. Chondrocytes from ﬁve OA subjects in primary
culture (a), proliferating primary culture (b) and subculture 1 (c) and from three subjects in subculture 2 (d) had been evaluated. Results are
expressed as pg of VEGF secreted by 105 cells incubated for 72 h in non-stimulated conditions (NS) or with IL-17 (50 ng/ml), IL-1b (100 U/ml),
TNF-a (100 U/ml), IL-17/IL-1b and IL-17/TNF-a. The boxes show 25th and 75th percentiles, the symbols the medians, and the vertical lines
below and above the boxes 10th and 90th percentiles. Statistical comparison was made using the Wilcoxon matched pairs test. *P!0:05 vs
NS and xP!0:05 vs IL-17-stimulated chondrocytes.
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Fig. 6. Effect of rVEGF and CCM on the proliferation of ECV304 cell line. Results are expressed as relative cpm increment, referred to the
percent increment of rVEGF-dependent proliferation considered as 100%. (a) Inhibition of rVEGF-stimulated ECV304 proliferation. ECV304
cell line received either rVEGF alone (black bar) or different concentrations of anti-VEGFR-2 antibody (ranging 50e1000 ng/ml) followed by
rVEGF ( gray bars) as previously described in Materials and Methods. Percentage means of rVEGF-dependent incrementGSD of triplicate
cultures are represented and are representative of two independent experiments. *P!0:05 vs rVEGF (Student’s t-test). (b) Effect of CCM on
ECV304 cell line proliferation. ECV304 cell line received rVEGF alone (black bar) or CCM containing VEGF at known concentrations
determined by ELISA (hatched bars) (sample 1: 5 ng/ml VEGF; sample 2: 6.05 ng/ml VEGF; sample 3: 0.27 ng/ml VEGF; sample 4: 1.05 ng/
ml VEGF; sample 5: 0.73 ng/ml VEGF). For inhibition assay, the ECV304 cell line was pre-incubated with 200 ng/ml anti-VEGFR-2 and then
stimulated with CCM ( gray bars). Experiments were performed in triplicate and the CCM-dependent increment of proliferation is expressed as
mean percentage of rVEGF-dependent incrementGSD and calculated as follows: [(CCM-stimulated cpmnon-stimulated cpm)/(rVEGF-
stimulated cpmnon-stimulated cpm)]!100. *P!0:05 vs VEGF (Student’s t-test); CCM-stimulated ECV304 cell line: anti-VEGFR-2
pretreated vs non-pretreated samples, P!0:05 (Wilcoxon matched pairs test).
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VEGF, an important contributor of synovial and cartilage
vascularization, is active during embryogenic development
and its maximal production has been ascertained as
occurring immediately before the cartilage ossiﬁcation and
bone formation32. The production of VEGF seems to be
only a peculiarity of hypertrophic chondrocytes from growth
plate of fetal and neonatal long bone, normally absent in
resting or proliferating chondrocytes32e34. The presence of
VEGF in normal adult cartilage is not easily determinable,
but it had been shown that OA chondrocytes can produce
high amounts of VEGF, and VEGF positive chondrocytes
have been found in OA cartilage in relation to the stage of
the disease12e14.
In this study we have shown that chondrocytes isolated
from cartilage of OA subjects are able to secrete VEGF as
well as chondrocytes from RA subjects. Inﬂammation
seems to play an important role in activating the VEGF
secretion by chondrocytes, because when we analyzed
chondrocytes from non-inﬂammatory pathology, we found
lower amounts of VEGF in comparison with OA and RA
chondrocytes. The higher vascularization in articular RA
tissues in comparison with articular tissues from OA
patients could be dependent on a higher secretion of other
angiogenesis factors by RA rather than OA chondrocytes,
or on a higher secretion of VEGF by RA rather than OA
synovial cells, also involved in articular pathological
modiﬁcations. The VEGF secretion strongly decreased in
about 12 days of culture, and continued to decrease until
the third passage in culture (which was reached in about 50
days) without disappearing. Other authors have shown that
in human articular chondrocytes the effect of a 42-day
culture was a complete loss of expression of VEGF gene35.
On the contrary, Carlevaro et al. demonstrated that culture
in suspension in adequate medium led to the condition of
differentiated chondrocytes, which maintain their ability to
synthesize high amounts of VEGF33. During the course of
OA the cartilage presents areas of matrix degradation and
remodeling where chondrocytes assume some character-
istics generally attributed to dedifferentiated chondro-
cytes36,37. For this reason, when we harvested cartilage
to obtain isolated chondrocytes, we avoided the region of
cartilage which presented major morphological anomalies.
This method selects a chondrocyte enriched population
from areas of cartilage that are scarcely affected by major
OA pathological modiﬁcations. When the chondrocytes
were isolated from these areas, they maintained their round
morphology for some days, then, cultured in monolayers,
they began to lose their typical morphology, proliferate and
dedifferentiate into ﬁbroblast-like cells27. It is known that
synovial ﬁbroblasts can be stimulated to produce VEGF by
IL-1b and TNF-a16,38. At this stage, we found that the strong
decrease of VEGF release matched an increase of
cathepsin B synthesis, which represents a ‘‘dedifferentiated’’
phenotype of chondrocytes23,39,40. On the basis of our
results, we suppose that freshly isolated chondrocytes are
representative of the phenotype of chondrocytes present in
cartilage regions with pathological modiﬁcations, but not
expressing a dedifferentiated feature. However, our data
have been obtained by an ‘‘in vitro’’ model and should be
conﬁrmed by analyzing the VEGF production from areas of
chondrocytes showing dedifferentiation markers in cartilage
samples from OA patients.
The differentiation status can inﬂuence the sensitivity
of chondrocytes to proinﬂammatory cytokines. IL-1b and
TNF-a inhibited VEGF production by freshly isolated humanchondrocytes, while IL-17 was ineffective. On the contrary,
when chondrocytes dedifferentiate and proliferate, IL-17, IL-
1b and TNF-a can increase the progressively reduced
VEGF production. We previously found that IL-1b and TNF-
a are strongly expressed in OA cartilage, together with IL-
17 receptor18,19. Furthermore IL-17 can also contribute to
the production of inﬂammatory chemokines by human
chondrocytes19.
In our model IL-17 modulated only the TNF-a ability to
decrease the VEGF secretion by freshly isolated chondro-
cytes, while it seemed not to affect either IL-1b decreased
or IL-1b and TNF-a increased VEGF secretion in primary
cultures or proliferating cultures and subcultures, respec-
tively. The linkage of cytokines to their receptor expressed
on cell surface can stimulate different cell activation
pathways. The different effect of IL-17 on IL-1b- and TNF-
a-dependent VEGF secretion by chondrocytes at passage
0e2 could be due to the utilization by chondrocytes of
activation pathways peculiar to each cell differentiation
status and differently interfering each other.
When the ECV304 cell line was stimulated by CCM
containing known VEGF concentrations, the increase of cell
proliferation was higher than that obtained with rVEGF and
not VEGF dose-dependent. This ﬁnding is not surprising,
because chondrocyte supernatants can also contain other
angiogenesis factors41,42. The partial inhibition of the
stimulating effect of CCM on the ECV304 cell line by
VEGFR-2 neutralization seems to conﬁrm the presence of
more factors stimulating ECV304 proliferation.
These proinﬂammatory cytokines present in the articular
microenvironment can contribute to neovascular formation
in the cartilage areas where proliferating chondrocytes
could assume a feature of hypertrophic/dedifferentiated.
The inﬁltration of cartilage by neovessels in the areas of
chondrocytes proliferation can contribute to altering the
characteristics of resistance depending on a normal carti-
lage architecture.
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